درباره این اپیزود

انگلیسی
ایالات متحده آمریکا

رونوشت 🔗

جستجوی اپیزودهای گذشته

اپیزودهای قبلی EHA 2015 را جستجو کن.

قسمت های دیگر در این پادکست

At a press conference at EHA 2015, Dr Mesa (Mayo Clinic Cancer Center, Scottsdale, USA) presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with …
Dr Hoffmann (Ludwig Maximilian University, Munich, Germany) talks to ecancertv at EHA 2015 about a web-based registry to record all newly-diagnosed chronic myeloid leukaemia (CML) patients in 20 European countries or pre-specified regions covering overall 92.5 million inhabitants. The researchers …
Dr Ehninger (University Hospital Dresden, Dresden, Germany) presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.
Dr Olga Guryanova (Memorial Sloan Kettering Cancer Center, New York, USA) presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به ecancer است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.